<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597762</url>
  </required_header>
  <id_info>
    <org_study_id>SiccaIkervis</org_study_id>
    <nct_id>NCT04597762</nct_id>
  </id_info>
  <brief_title>Effect of Ciclosporin Eyedrops on Sjögren Syndrome</brief_title>
  <official_title>Effect of Ciclosporin Eyedrops on Ocular Symptoms and Optical Quality in Patients With Sjögren Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Hietzing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Hietzing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keratoconjunctivitis sicca, also known as dry eye syndrome, is one of the most common&#xD;
      ophthalmological diseases and is treated with tear substitutes to moisten the surface of the&#xD;
      eye and, in more severe cases of this disease, with local anti-inflammatory therapy with&#xD;
      corticosteroids or ciclosporin A. In patients with rheumatological diseases, such as&#xD;
      Sjögren's syndrome, dry eye syndrome of severe extent occurs particularly frequently, which&#xD;
      is why topical anti-inflammatory therapy is often necessary in these patients.&#xD;
&#xD;
      Aim of this study is to evaluate the treatment of severe dry eye syndrome with topical&#xD;
      cyclosporin eyedrops with and without topical corticosteroids at the beginning of the&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tearfilm breakup time</measure>
    <time_frame>6 months</time_frame>
    <description>tearfilm breakup time measured with Fluorescein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal fluorescein staining</measure>
    <time_frame>6 months</time_frame>
    <description>corneal fluorescein staining staged with Oxford grading scale, ranging from 0 (no staining) to 5 (maximal staining)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal optical aberrations</measure>
    <time_frame>6 months</time_frame>
    <description>corneal optical aberrations measured with iTrace aberrometry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment with Ciclosporin eyedrops for the right eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the left eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment with Ciclosporin eyedrops for the left eye and Ciclosporin eyedrops + Hydrocortisone eyedrops for the right eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin</intervention_name>
    <description>Cyclosporin eyedrops</description>
    <arm_group_label>left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone</arm_group_label>
    <arm_group_label>right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone eyedrops</description>
    <arm_group_label>left eye: Ciclosporin, right eye: Ciclosporin + Hydrocortisone</arm_group_label>
    <arm_group_label>right eye: Ciclosporin, left eye: Ciclosporin + Hydrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of severe keratoconjunctivitis sicca defined by:&#xD;
&#xD;
          -  Staining of the cornea ≥ grade III according to the Oxford scale&#xD;
&#xD;
          -  OSDI value ≥ 12&#xD;
&#xD;
          -  Age between 18 and 90 years&#xD;
&#xD;
          -  Primary or secondary Sjogren's syndrome (defined according to the American-European&#xD;
             Consensus Group criteria) with a stable course and unchanged treatment for 6 months&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy (excluded with a pregnancy test in patients of childbearing potential)&#xD;
&#xD;
          -  Children and young people up to the age of 18&#xD;
&#xD;
          -  Eye surgery in the past 6 months&#xD;
&#xD;
          -  Simultaneous participation in another study&#xD;
&#xD;
          -  Regular use of eye drops, with the exception of tear substitutes&#xD;
&#xD;
          -  Use of eye drops containing ciclosporin or glucocorticoids in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Augenabteilung - Klinik Hietzing</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Hietzing</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Pia Vécsei-Marlovits</investigator_full_name>
    <investigator_title>Pro. Dr. Pia Vécsei-Marlovits</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

